Boundless Bio Appoints Shailaja Kasibhatla, Ph.D., as Vice President, Discovery and Translational Development

– Dr. Kasibhatla brings deep drug development expertise across multiple mechanisms of action and therapeutic modalities, as well as a strong foundational understanding of tumor-intrinsic and immuno-oncology targets, to Boundless Bio –

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that it has appointed Shailaja Kasibhatla, Ph.D., as Vice President, Discovery and Translational Development.

“We’re delighted to welcome Shailaja to our growing team,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “She brings a wealth of experience in oncology drug development that will be extremely valuable as we work to advance our programs into the clinic and bring new therapies to patients with gene amplification driven cancers.”

Dr. Kasibhatla has more than 20 years of experience in the pharmaceutical industry and has contributed to the advancement of more than 10 programs towards clinical proof of concept. Prior to Boundless Bio, she served as Senior Director of Translational Development at Bristol-Myers Squibb (BMS) where she led the cohesive scientific and strategic integration of early translational development across multiple protein degrader programs and managed these programs from preclinical to clinical proof of concept.

Prior to joining BMS, Dr. Kasibhatla spent eight years at Novartis (Genomics Institute of the Novartis Foundation) where she built a world-class, integrated discovery, pharmacology, and translational oncology group that advanced a diverse portfolio of oncogenic and immuno-oncology programs into the clinic. While at Novartis, her team contributed to the successful approval of Zykadia^TM (ceritinib), a breakthrough therapy for ALK-driven non-small cell lung cancer. Prior to Novartis, Dr. Kasibhatla was at Merck Research Labs (MRL) where she led the pharmacology group and was responsible for driving multiple tumor-targeted therapeutic strategies.

She holds a Ph.D. in Immunology and Genetics from Osmania University in Hyderabad, India, and completed a postdoctoral fellowship at the Dana Farber Cancer Institute (DFCI) at Harvard Medical School.

“I’m thrilled to join this talented team of proven and passionate industry veterans,” said Dr. Kasibhatla. “Boundless Bio is the foremost company interrogating ecDNA biology, and I look forward to helping the team develop personalized cancer treatments for intractable cancers.”

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.